Status of nevirapine non-assert declarations (August 2007):
Boehringer Ingelheim has provided the following companies with non-assert declarations: Aspen (South Africa), Aurobindo (India), Cipla (India), Ranbaxy and Strides (both India); further non-assert-declarations are in process.
In addition, Boehringer Ingelheim is willing to grant and has offered a royalty-free licence for production of nevirapine in Canada and export to Rwanda as part of a triple combination (TRIZIVIR).